SAB Biotherapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
SAB Biotherapeutics R&D Spending Growth & History (SABS)
SAB Biotherapeutics's r&d spending was $34.4M for fiscal 2025.
View full SAB Biotherapeutics company overviewSAB Biotherapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $34.4M | $4.1M | +13.56% |
| 2024 | 2024-12-31 | $30.3M | $13.7M | +83.18% |
| 2023 | 2023-12-31 | $16.5M | −$19.9M | −54.68% |
| 2022 | 2022-12-31 | $36.4M | −$20.7M | −36.28% |
| 2021 | 2021-12-31 | $57.2M | $29.3M | +104.90% |
| 2020 | 2020-12-31 | $27.9M | — | — |
SAB Biotherapeutics quarterly r&d spending
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $16.2M | $9.2M | +131.13% |
| Q1 2026 | 2026-03-31 | $13.4M | $5.7M | +74.97% |
| Q4 2025 | 2025-12-31 | $10.7M | $3.3M | +43.95% |
| Q3 2025 | 2025-09-30 | $9.0M | $1.1M | +14.55% |
| Q2 2025 | 2025-06-30 | $7.0M | $174,802 | +2.56% |
| Q1 2025 | 2025-03-31 | $7.7M | −$488,749 | −6.00% |
| Q4 2024 | 2024-12-31 | $7.5M | $3.2M | +73.42% |
| Q3 2024 | 2024-09-30 | $7.8M | $3.8M | +94.81% |
| Q2 2024 | 2024-06-30 | $6.8M | $3.2M | +86.29% |
| Q1 2024 | 2024-03-31 | $8.1M | $3.6M | +79.60% |
| Q4 2023 | 2023-12-31 | $4.3M | −$2.9M | −40.12% |
| Q3 2023 | 2023-09-30 | $4.0M | −$3.3M | −45.33% |
| Q2 2023 | 2023-06-30 | $3.7M | −$4.9M | −57.34% |
| Q1 2023 | 2023-03-31 | $4.5M | −$8.8M | −65.96% |
| Q4 2022 | 2022-12-31 | $7.2M | −$3.5M | −32.60% |
| Q3 2022 | 2022-09-30 | $7.4M | −$7.7M | −51.21% |
| Q2 2022 | 2022-06-30 | $8.6M | −$10.1M | −54.05% |
| Q1 2022 | 2022-03-31 | $13.3M | $542,340 | +4.24% |
| Q4 2021 | 2021-12-31 | $10.6M | — | — |
| Q3 2021 | 2021-09-30 | $15.1M | — | — |
| Q2 2021 | 2021-06-30 | $18.7M | — | — |
| Q1 2021 | 2021-03-31 | $12.8M | — | — |
SAB Biotherapeutics r&d spending trends
Over the last five fiscal years, SAB Biotherapeutics's r&d spending increased from $27.9M to $34.4M, a change of $6.4M. The latest reported quarter, Q2 2026, shows $16.2M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review SAB Biotherapeutics source filings ↗